Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B |
Gross Profit | 1.02B | 820.57M | 791.46M | 783.95M | 628.39M |
EBITDA | 439.77M | 399.76M | 150.43M | 401.10M | 345.61M |
Net Income | -116.89M | -83.99M | -129.99M | 10.62M | 91.06M |
Balance Sheet | |||||
Total Assets | 3.50B | 3.47B | 3.80B | 3.94B | 4.01B |
Cash, Cash Equivalents and Short-Term Investments | 110.55M | 93.74M | 27.80M | 248.96M | 341.38M |
Total Debt | 2.59B | 2.75B | 2.85B | 2.88B | 2.94B |
Total Liabilities | 3.61B | 3.45B | 3.59B | 3.57B | 3.66B |
Stockholders Equity | -109.27M | 19.78M | 298.42M | 360.34M | 344.93M |
Cash Flow | |||||
Free Cash Flow | 243.18M | 276.39M | -25.50M | 189.18M | 312.81M |
Operating Cash Flow | 295.10M | 345.58M | 65.10M | 241.82M | 379.00M |
Investing Cash Flow | -63.00M | -69.19M | -174.31M | -194.18M | -317.55M |
Financing Cash Flow | -211.79M | -212.57M | -106.62M | -138.12M | 131.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $1.45B | ― | -5.19% | ― | 30.26% | -173.36% | |
71 Outperform | $1.85B | 29.85 | 6.32% | ― | 11.82% | ― | |
68 Neutral | $1.06B | 8.17 | 19.90% | ― | 8.05% | -8.46% | |
63 Neutral | $3.86B | ― | -3.64% | 4.03% | -4.85% | -4290.31% | |
56 Neutral | $2.51B | ― | 106.97% | ― | 13.42% | 92.50% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
49 Neutral | $2.76B | 27.16 | 128.44% | ― | 539.47% | ― |
On July 24, 2025, Amneal Pharmaceuticals announced that its subsidiary priced a $600 million offering of senior secured notes due 2032, reduced from the initially planned $750 million. The company plans to use the proceeds from these notes and a $2.1 billion term loan to refinance existing loans and repay outstanding amounts, with the offering expected to close on August 1, 2025, subject to customary conditions.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
On July 21, 2025, Amneal Pharmaceuticals announced that its subsidiary, Amneal Pharmaceuticals LLC, is seeking to borrow $1.8 billion in new seven-year term B loans and has launched a $750 million private offering of senior secured notes due 2032. The proceeds from these financial activities are intended to refinance existing term B loans, repay a portion of outstanding amounts under its ABL facility, and cover related fees and expenses. These transactions are subject to market conditions, and there is no assurance of their completion. The notes will be offered to qualified institutional buyers and non-U.S. persons, and will not be registered under the Securities Act of 1933.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Amneal Pharmaceuticals announced a reduction in its Board of Directors from six to five members due to a decrease in the ownership of Class A Common Stock by the Amneal Group. This led to the resignation of Emily Peterson Alva from the Board on July 16, 2025. The company also reported preliminary financial results for the second quarter of 2025, showing a net revenue increase of approximately 3% and a significant rise in income before taxes compared to the same period in 2024. The results highlight Amneal’s continued financial strength and deleveraging efforts, with expectations to meet or exceed full-year guidance. The quarter also saw the FDA approval of Brekiya® autoinjector and strong commercial uptake of CREXONT®, positioning Amneal well for future growth.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Amneal Pharmaceuticals held its 2025 Annual Meeting of Stockholders on May 6, 2025, where all proposals were approved, and all director nominees were elected. The meeting included the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These approvals are expected to support the company’s governance and operational strategies moving forward.
Amneal Pharmaceuticals reported strong financial results for the first quarter of 2025, with net revenue reaching $695 million, a 5% increase from the previous year. The company achieved a net income of $12 million, a significant improvement from a net loss of $92 million in the same quarter of 2024, driven by higher revenue, gross profit, and the absence of a previous legal settlement charge. The company also reported an adjusted EBITDA of $170 million, reflecting a 12% increase, and affirmed its full-year 2025 financial guidance, indicating confidence in its growth trajectory and value creation for stakeholders.